Evidence map›Paper›PMID 27014277›Full record

ArticleFrontiers in immunology2016

Impact of MIF Gene Promoter Variations on Risk of Rheumatic Heart Disease and Its Age of Onset in Saudi Arabian Patients.

Atiyeh M Abdallah, Abdulhadi H Al-Mazroea, Waleed N Al-Harbi, Nabeeh A Al-Harbi, Amr E Eldardear, Yousef Almohammadi, Khalid M Al-Harbi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Impact of theFrontiers in cardiovascular medicine · 2024
    Review
  3. The Impact ofDiagnostics (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Association ofInternational journal of clinical and experimental pathology · 2021
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Atiyeh M AbdallahWest Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust , Birmingham , UK.
Abdulhadi H Al-MazroeaPediatric Department, Maternity and Children Hospital, Ministry of Health, College of Medicine, Taibah University , Al-Madinah , Saudi Arabia.
Waleed N Al-HarbiPediatric Department, Maternity and Children Hospital, Ministry of Health, College of Medicine, Taibah University , Al-Madinah , Saudi Arabia.
Nabeeh A Al-HarbiPediatric Department, Maternity and Children Hospital, Ministry of Health, College of Medicine, Taibah University , Al-Madinah , Saudi Arabia.
Amr E EldardearPediatric Department, Maternity and Children Hospital, Ministry of Health, College of Medicine, Taibah University , Al-Madinah , Saudi Arabia.
Yousef AlmohammadiSecurity Forces Medical Centre , Al-Madinah , Saudi Arabia.
Khalid M Al-HarbiPediatric Department, Maternity and Children Hospital, Ministry of Health, College of Medicine, Taibah University , Al-Madinah , Saudi Arabia.
Taibah University · SABirmingham Women’s and Children’s NHS Foundation Trust · GBMinistry of Health · SASecurity Forces Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although macrophage migration inhibitory factor (MIF) has consistently been shown to be an important immune modulator, data on the association between MIF promoter variations and the risk of developing rheumatic heart disease (RHD) remain inconclusive. RHD is an important complication of streptococcal infections in the Middle East, not least in Saudi Arabia, and identifying risk markers is an important priority. Therefore, we investigated the association between two functional MIF promoter variations and RHD susceptibility and severity in Saudi patients: the MIF-173G > C substitution (rs755622) and the MIF-794 CATT5-8 tetranucleotide repeat (rs5844572). Three hundred twenty-six individuals (124 RHD patients and 202 age-, sex-, and ethnically matched healthy controls) were genotyped using allelic discrimination and fragment analysis. Data were analyzed with respect to disease susceptibility, severity, sex, and age of onset. There was a significantly lower frequency of 173C allele carriage in RHD patients compared to controls [odds ratio (OR) = 0.47; 95% confidence intervals (CIs) = 0.28-0.77; p = 0.003]. Interestingly, the 173C allele was associated with late disease onset (p = 0.001). The 794 5-repeat allele was associated with decreased RHD risk (OR = 0.56; 95% CIs = 0.38-0.82; p = 0.003). In contrast, the 794 6-repeat allele was associated with increased risk of RHD (OR = 1.7; 95% CIs = 1.2-2.5; p = 0.002). MIF promoter variations appear to have a dual role in RHD, with 173C allele non-carriers at higher risk of developing RHD at a younger age. These results require further validation in larger multi-ethnic cohorts, and functional studies are necessary to understand the underlying molecular mechanisms driving the at-risk phenotype.

Indexed as

age of onsetmigration inhibitory factorpolymorphismsrheumatic heart diseaseSaudi Arabia

Identifiers

PMID27014277
PMCPMC4790191
OpenAlexW2312695500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.